ABSTRACT
Introduction
Current therapies for advanced disseminated melanoma or locally advanced disease remain seriously inadequate with typically poor clinical responses, high failure rates even when responses do occur, and options for any subsequent therapy are severely limited. Immunotherapy using vaccines has been used previously, but most studies have not persisted with continued vaccinations when disease progression has occurred, and especially when chemotherapy is administered, typically using either Dacarbazine (DTIC) or Fotemustine, which are considered as the standard treatment agents. These standard chemotherapy agents are often regarded as essentially palliative for ameliorating symptoms from metastases, but to our knowledge have seldom been tested with concurrent vaccine or other immunotherapies, apart from the interferons. Despite trials and comparisons with a variety of other chemotherapeutic and biologic agents and combinations of agents, little improvement has been possible upon standard agents. However, progression free survivals are usually less than 2 months with median overall survival from 6-9 months, with any form of systemic therapy. Percent survivals at 1-year in response to DTIC and a variety of agents is approximately 25% [1] , however this reduces substantially to < 2% at 2-5 years [2] . Immunotherapy with dendritic cell vaccines has been effective in a number of small studies, but results have generally not justified the complex and expensive production procedures. Immunotherapy with traditional vaccines has received limited evaluation, and those available have results at least as effective as those with DTIC (reviewed by Hersey 2004) [3] . Surgery for isolated metastases may be an option in highly selected patients with localised Stage IV or Stage IIIc melanoma, but this option is usually unavailable or ineffective for treatment of widespread metastatic disease.
Vaccinia Melanoma Cell Lysate (VMCL) vaccine therapy, consisting of a vaccinia virus lysed, allogeneic melanoma cell line, has been previously described [4, 5] and was used in a previous Australian randomised clinical trial for earlier-stage, completely resected high-risk melanoma [6] . Although no statistically apparent overall survival benefit (p = 0.068) could be shown for the VMCL vaccine treated group over the untreated controls in Stage IIb and III melanoma patients, the survival of vaccine treated patients remained above that of the non-treated patients, indicating a possible 'positive effect' in some patients. The VMCL vaccine was shown to be very safe and demonstrated low or no toxicity in over 700 patients given the vaccine for 2 years [6] . However, no formal studies had been done in patients with residual advanced disease, so a pilot study was done in patients with advanced surgically non-resectable stage IV/ IIIc metastatic melanoma (some after prior chemotherapy), to examine whether immunotherapy with this vaccine may be of benefit in this patient group; and whether combination with DTIC or Fotemustine may further improve its efficacy. The main aim in the study was to investigate the feasibility of use of sustained, repeated dosing of the VMCL vaccine for potential therapy in patients with advanced unresectable melanoma to observe if any effect appeared to be present, and if disease progression occurred, vaccine would be continued during added chemotherapy. Endpoints were primarily measurement of overall survival, but morbidity and toxicity were also recorded, and in addition response rates were noted secondarily.
Methods

Patient Characteristics
The median age of the thirty-seven [37] patients enrolled in the studies was 59 years, with a mean age of 61 and age range of 35 to 97 years. All patients were evaluable for follow-up from 4 to 73 months after commencement of vaccine therapy, with a mean of 23.5 months follow-up and a median 10 months. No patients were lost to follow-up.
All patients had either advanced non-surgically re- Most patients were offered therapy provided their disease was advanced and not amenable to surgical resection.
VMCL Vaccinations
Vaccinations were at regular 2-weekly intervals for 6 months; then monthly for 6 months. If stabilisation/ complete response was obtained, then doses were given 3-monthly thereafter. Intra-dermal injection sites were rotated between upper outer aspects of all 4 limbs, but avoided in any limb where lymph node dissection was performed, to avoid inducing any lymphoedema. 0.3 ml of the re-suspended, sonicated, lysate was determined as safe and practical from the previous studies of VMCL vaccine [5] . Although only minimal skin reactions were observed in previous Stage II/III melanoma studies, precautionary resuscitation facilities were available and patients were observed for 0.5-1 hour after the 1 st and 2 nd vaccinations.
Skin DTH Testing & Responses
These were performed using the 1 st and again at the 4 th VMCL vaccination dose (each read-out 48 hours later; erythema and the induration responses were independently recorded in two directions perpendicular to each other; > 10 mm was positive) at the vaccination sites, after ensuring that no inflammatory response pre-existed.
Chemotherapy
If the patient showed melanoma disease-progression during vaccine therapy, the protocol allowed for addition of standard chemotherapy with either Dacarbazine (DTIC) (850 mg/ m 2 at 3-weekly intervals intravenously), or Fotemustine (100 mg/ m 2 weekly intravenously for 3 weeks, followed by a 5 week break, then 3 weekly thereafter). Vaccinations were maintained at 2-weekly intervals over the chemotherapy period and during breaks in chemotherapy.
Clinical End-points
Primary End-point Overall survival was the primary end-point assessed by survival in months from the time of commencement of vaccination to the date of analysis or death of the patient.
Secondary End-points 1) Toxicity and tolerability, in terms of local or systemic reactions, was examined with each vaccination and recorded.
2) Tumour response rates were also recorded, assessed by the WHO [7] criteria. Observable subcutaneous lesions were assessed using two perpendicular direct size measurements using calipers or a ruler, and internal metastases were assessed using CT scans at 3-monthly intervals or as clinically otherwise determined, and where appropriate using ultrasound, MRI or Positron Emission Tomographic (PET) scans.
Statistical Analysis
This was performed using standard means and median calculations, Kaplan-Meier analysis and time-series analysis with the assistance of our statistician and mathematician (NB; AC). All analyses were set at a significance level of 0.05 in the initial analyses.
Results Clinical Outcomes
Primary Endpoint-Overall Survival
Statistical analysis was performed on data collected to the end of 2006, with a median overall follow-up at this time (to either death or date of analysis) of 10 months. Overall survival for all 37 patients ranged from ranged from 4 to 73 months with a mean survival of 23.5 months and median survival of 10 months. Nine (9) of the 37 (24.3%) patients survived greater than 23 months, ranging from 1.9 -6.1 years. The characteristics of these 9 patients are shown in Table 2 . Organ and/ or lymph node metastases in 7 of 9 patients (78%), and multiple subcutaneous metastases alone were present in 2 of 9 
patients (22%).
For the entire group, at the end of the survey period 9 (24.3%) patients were alive and well, and 28 (75.7%) had died. The median survival time of the 9 patients still alive was 25 months from vaccine commencement, and in 5 of these patients the median survival time was 45 months. The survival times for the individual 37 patients along with the treatments given and the timing of these treatments are shown as a bar-chart in Figure 1 .
Nearly half the patients (15) survived beyond 12 months and 9 patients survived for longer than 23 months. More detailed description of the patients surviving to the 2-year time-point or beyond is given in Table  3 . This showed that 3 had M1c, 1 M1b and 5 M1a stage melanoma and most had failed prior radiotherapy (1), surgical metastatectomy (6), biological therapy (2) and ILI chemotherapy (1), two had received no prior therapy.
A Kaplan-Meier analysis was performed which demonstrated an overall survival at 1, 2, and 5 years was 40.5%, 21.6% and 10.8% respectively. These survivals compare vary favourably with the 1-and 2-year survivals of 25% and 10% [1] and 30% and 11% [2] respectively, in previous studies [1,2,8; see Table 3 ]. 5-year survivals are uniformly low at < 2% in most studies.
Duration of Survival
The survival times of patients from the time of commencement of vaccination until either death, or the time of evaluation were analyzed by stratification into 6- 
Clinical Disease Responses
Clinical responses were considered as secondary end-points, as these were related to, but separate from, overall survival. This was especially so for CRs, as ex pected, but PRs were also observed to be associated with marked clinical melanoma regression (Figure 3) , devel- 16 .2 % (6) of patients, but 1 or 2 lesions in these patients showed mild erythema or minor size reduction of some lesions, which were sometimes short-lived (< 6 weeks), however, these were not counted as 'responses'. Progressive Disease (PD) was the cause of death in all 28 (75.7%) who had died at the end of the study period. No patient died of non-melanoma related causes.
Toxicity
Anaphylaxis or allergy was not observed. No local or systemic toxicity was observed at any stage from the vaccinations during the studies. Minor skin irritation or unexplained dizziness was rare. Chemotherapy toxicity was of the same profile observed with standard chemotherapy for metastatic melanoma, and unaffected by concomitant vaccination. Side-effects of chemotherapy were generally mild with no grade 4 toxicity observed. Three patients required dose delay because of grade 3 neutropenia. Two patients stopped chemotherapy after one cycle due to disease progression and patient choice.
DTH Responses
No measurable DTH responses against VMCL were detected at either of the time-points tested in any of the 37 patients in the studies.
Prior Failed Clinical Treatment Type
Of the 37 patients, 20 patients (54%) had failed previous non-surgical treatments; 14 (37.8%) had failed previous chemotherapies (DTIC, Fotemustine, ILI chemotherapy, other biological therapies), and a further 6 (16.2%) had failed Radiotherapy alone; refer to Table 4 and Figure 1 . 
Discussion
A possible innovative role for combined continued immuno-chemotherapy is suggested by these results in the treatment of advanced non-resectable melanoma that has (usually) failed surgery and/or other therapies. The results shown above indicate that repeated vaccine therapy, with or without concomitant standard chemotherapy was effective in inducing complete regression of advanced melanoma in nearly 20% of patients and appeared to slow melanoma growth in over 60% of patients with mean survivals of 23.5 months and 1, 2 and 3 year survivals of 40.5, 21.6 and 10.5% respectively. An as yet undefined mechanism appears to be operating to produce these observations. The above findings compare favourably with the pooled results from the cooperative group studies reported by Korn et al. [1] , which appear to have similar patient entry criteria. Our results were unexpected, as many patients had failed (often multiple) previous therapies and had extensive disease. Furthermore, one quarter of the patients (24.3%; 9) survived over 23 months, since commencement of vaccination, and long-term durable responses of between 4 and 6 years were obtained in 4 (10.8%) patients. Interestingly, not all of these patients had CR's to explain their clinical course with repeated vaccination. At the end of the survey period, out of the 37 patients included in the study, 9 (24.3%) patients were alive and well, and 28 (75.7%) had died. Almost half (46%; 17) of the patients were observed to develop stable disease (SD), despite having extensive disease. Somewhat predictably, overall survival was associated with clinical responses. This was especially so for CRs, but surprisingly to us, PRs were also observed to be associated with development of stable disease and prolonged survival, even in some patients with high disease burden. This suggests some true effect of repeated vaccination therapy, and possibly additional chemotherapy enhancement, although the direction of the effect (ie. which therapy is enhancing which) is presently unclear.
Although the results shown above are suggestive that immunotherapy with VMCL ± chemotherapy may be of benefit in extending the survival of some patients with melanoma, it is of course appreciated that interpretation in smaller uncontrolled studies may be confounded. However, the very fact that any patients could demonstrate prolonged survivals was remarkable, and that disease progression appeared to be halted, at least for some considerable time in some patients. Although inadvertent patient selection is difficult to completely exclude, nevertheless, over 2/3 of patients in the present study had much less favourable stage IV M1b/c disease and included a spectrum of patients with advanced disease. The importance of stage of disease on metastatic melanoma is well reported, for example in large patient groups, 1 and 2 year survivals for M1a disease were 54% and 36% respectively compared to 35% and 18% respectively for patients with M1c disease [8] . In addition, some patients had failed/ relapsed prior to entry and some had received two or more forms of prior therapy as shown in Table 4 , where surgical metastatectomy included local and organ metastatic disease resections; prior chemotherapy was standard systemic therapy and/or ILI chemotherapy; biological trial therapies included IL-18; Canvaxin; NY-ESO-1; Interferon; and P-188 therapy.
The standard use of dacarbazine (DTIC) and Fotemustine, and in some countries multi-dose regimens, have not been able to substantially alter the survival of advanced metastatic melanoma, and are regarded as essentially 'palliative'. Despite hope that interleukins, interferons and other bio-therapeutic agents would improve outcome, this has not proved to be the case, and are often limited by significant toxicity [9] . Prior studies with both DTIC and Fotemustine alone have reported response rates of 5-15%, and complete response rates of 0.8-2.7% with median survival times of 5-8 months in patients with advanced melanoma. No benefit was observed with multi-agent over single agent chemotherapy [10] [11] [12] . Korn [1] in a meta-analysis of 42 phase 2 trials involving 2027 patients reported a median survival time of 6.2 months (95% CI; 5.9-6.5 months). Percent survival at 1-year was 25.5%. Bedikian [2] reported that DTIC induced a median survival of 7.8 months and approximately a 30% 1-year survival. Overall response was 7.5% and a 0.8% complete response rate in 395 patients. In the present studies we observed that 15 patients (40.5%) survived 12 months or more. Our observed initial complete response rate (CR) of all clinical and radiological tumour was 18.9% (7) of patients. This remained durable beyond 18 months (Alive + CR) in 10.8% (4) of patients. Any Clinically Measurable Response was demonstrated in 83.7% (31) of patients despite many of these patients had already failed standard (multiple) therapies before entry to our study.
A potentially significant point of difference between this and previous studies is that we chose to continue regular vaccine administration for a long time period irrespective of continued tumor growth [13] . Furthermore, we also continued repeated VMCL vaccination during any chemotherapy delivery, rather than stopping vaccination entirely or even temporarily, as others have done in the past.
Whether DTIC (or fotemustine) added substantially to the benefit of immunotherapy, or the reverse was true, is not clear from this limited study, but it is our impression that combined vaccine and chemotherapy in patients with progressive disease enhanced the clinical effectiveness and importantly was capable of producing either CR or stable disease, with the net effect of prolonging overall survival. The combined additive effect of vaccine and chemotherapy might be explained by either increased antigen release due to chemotherapy, or ablation of T-regulatory cells by chemotherapy or both [14, 15] . The timing of the administration of the VMCL Vaccine and/ or chemotherapy may be of importance in determining the clinical outcome and is the subject of on-going studies [16, 17] . Previous work has shown that intra-tumoural dendritic cell (DC) numbers or poor DC activation/ presentation may play a significant role in directing the anti-tumor response and outcome [18] [19] [20] [21] [22] [23] [24] , perhaps through T-cell immunosuppression [25] [26] [27] [28] . The T-effector cells and T-regulatory cell balance in the tumour microenvironment is of likely critical importance in determining outcome in a variety of cancers [29] [30] [31] [32] [33] [34] and further studies are needed to examine these aspects.
In summary, treatment with the VMCL Vaccine has proven to be safe, with no or very low toxicity, and appears to induce significant improvement in overall survival in some 40% of patients with advanced melanoma. It is capable of inducing complete regression of melanoma, and some of these are durable for long periods, extending to over 6 years. Stable disease can be induced with or without partial responses in some lesions. If disease progresses, the VMCL vaccine can be safely combined and continued with standard chemotherapy using DTIC or fotemusine, and this has added to its effectiveness in a number of patients. The tumour growth modulation producing resolution, regression, and stabilization of melanoma deposits in patients, is likely due to immunomodulation due to repeated dosing of vaccine continuously with or without concurrent chemotherapy. Further evaluation of combined vaccine and chemotherapy in a randomized trial appears warranted.
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